OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma

October 7th 2020

Alexander N. Shoushtari, discusses the rationale for the phase 3 CheckMate-067 trial in advanced melanoma.

Dr. Paplomata on the Clinical Impact of Tucatinib in HER2+ Breast Cancer

October 7th 2020

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.

Dr. Petrylak on the Utility of Tissue Versus Liquid Biopsy in Prostate Cancer

October 7th 2020

Daniel P. Petrylak, MD, discusses the utility of tissue biopsy versus liquid biopsy in prostate cancer.

Dr. Doroshow on the Impact of the COVID-19 Pandemic on Cancer Care

October 7th 2020

Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.

Dr. Seymour on the Efficacy Ibrutinib Versus Chemoimmunotherapy in Older Patients With CLL

October 7th 2020

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.

Dr. Deol on the Utility of Tisagenlecleucel in ALL

October 7th 2020

Abhinav Deol, MD, discusses the approval of the CAR T-cell therapy tisagenlecleucel for pediatric patients with acute lymphoblastic leukemia.

Dr. Lonial Discusses Ongoing Research With BiTEs and CAR T-Cell Therapy in Myeloma

October 6th 2020

Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.

Dr. Hamilton on the Exploration of CDK4/6 Inhibitors in Breast Cancer

October 6th 2020

Erika P. Hamilton, MD, discusses the exploration of CDK4/6 Inhibitors in HER2-positive breast cancer.

Dr. Davids on the Use of Chemoimmunotherapy in CLL

October 6th 2020

Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Dr. Hussain on the Need for Collaboration to Cure Prostate Cancer

October 6th 2020

Maha Hussain, MD, FACP, FASCO, discusses the need for collaboration to cure patients with prostate cancer.

Dr. Pautier on Challenges With Drug Development in Leiomyosarcoma

October 6th 2020

Patricia Pautier, MD, discusses limitations in leiomyosarcoma.

Dr. Gajra on Adverse Effects Associated With CAR T-Cell Therapy in Hematologic Malignancies

October 6th 2020

Ajeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.

Dr. Verstovsek on the Different Phases of MPNs

October 6th 2020

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Dr. Gainor on the Evolving Lung Cancer Armamentarium

October 5th 2020

Justin F. Gainor, MD, discusses the evolving lung cancer armamentarium.

Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL

October 5th 2020

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.

Dr. Azad on the Benefit of Adding Enzalutamide to ADT in mHSPC

October 5th 2020

Arun Azad, PhD, discusses the utility of adding enzalutamide to androgen deprivation therapy in subgroups of men with metastatic hormone-sensitive prostate cancer.

Dr. Tseng on the Rationale for the TARPSWG Analysis in Retroperitoneal Sarcoma

October 5th 2020

William W. Tseng, MD, discusses the rationale for the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Dr. Masarova on the Safety of JAK Inhibitor/Targeted Therapy Combos in Myelofibrosis

October 5th 2020

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.

Dr. Vesole on the Advantages of CAR T-Cell Therapy in Multiple Myeloma

October 5th 2020

David H. Vesole, MD, PhD, discusses the advantages of CAR T-cell therapy in multiple myeloma.

Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast Cancer

October 3rd 2020

Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.